Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep is now Phase 3-ready

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 17, 2023 2:38pm

103 Views

Post# 35501900

RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep is now Phase 3-ready

Current share price has nothing to do with the acquisition price. Anyone who has their "eyes rolled" is not living in the "real world" of today and instead is trying to rely on old net present valuation (NPV) models that have no practical application in early - late stage "biologically based" biotech companies who are presently not generating income.

Regardless of their protests to the contrary, they are more the FUD types that have been here posting that kind of "stuff" for many years.

<< Previous

Bullboard Posts

Next >>

Three high-conviction small-cap stocks across the risk spectrum